Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoffer Valdemar Nissen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|March 18, 2014
[Uncombable hair syndrome]Christoffer Valdemar Nissen, Mathias Tiedemann Svendsen
Ugeskrift for Laeger|May 30, 2012
[Aplasia Cutis Congenita]Christoffer Valdemar Nissen, Mathias Tiedemann Svendsen, Jesper Fenger-Grøn
Photodiagnosis and Photodynamic Therapy|December 7, 2019
Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modalityHans Christian Wulf, Christoffer Valdemar Nissen, Peter Alshede Philipsen
Ugeskrift for Laeger|November 13, 2024
Rami Nabil Al-Chaer, Mette Mogensen, Ulla Feldt-Rasmussen, et al.
Ugeskrift for Laeger|January 9, 2023
Mathilde Tuborg Andersen, Ewa Anna Burian, Christoffer Valdemar Nissen, et al.
Pigment Cell & Melanoma Research|June 25, 2019
A novel LC-MS/MS method to quantify eumelanin and pheomelanin and their relation to UVR sensitivity - A study on human skin biopsiesCatharina Margrethe Lerche, Peter Olsen, Christoffer Valdemar Nissen, et al.
Diagnostics (Basel, Switzerland)|May 13, 2026
Edema as a Key Presentation of Acrodermatitis Chronica Atrophicans: A Retrospective Cohort Study from a Tertiary Setting in Denmark 2017-2025Otto Scharff El-Nasser, Helene Mens, Nanna Skaarup Andersen, et al.
American Journal of Clinical Dermatology|October 13, 2024
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort StudyMette Gyldenløve, Christoffer Valdemar Nissen, Sascha Dinsen Wreschner Stave, et al.
Dermatologic Therapy|September 1, 2020
Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasisValdemar Wendelboe Nielsen, Tamara Theresia Lund, Robert Gniadecki, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|March 18, 2014
[Uncombable hair syndrome]Christoffer Valdemar Nissen, Mathias Tiedemann Svendsen
Ugeskrift for Laeger|May 30, 2012
[Aplasia Cutis Congenita]Christoffer Valdemar Nissen, Mathias Tiedemann Svendsen, Jesper Fenger-Grøn
Photodiagnosis and Photodynamic Therapy|December 7, 2019
Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modalityHans Christian Wulf, Christoffer Valdemar Nissen, Peter Alshede Philipsen
Ugeskrift for Laeger|November 13, 2024
Rami Nabil Al-Chaer, Mette Mogensen, Ulla Feldt-Rasmussen, et al.
Ugeskrift for Laeger|January 9, 2023
Mathilde Tuborg Andersen, Ewa Anna Burian, Christoffer Valdemar Nissen, et al.
Pigment Cell & Melanoma Research|June 25, 2019
A novel LC-MS/MS method to quantify eumelanin and pheomelanin and their relation to UVR sensitivity - A study on human skin biopsiesCatharina Margrethe Lerche, Peter Olsen, Christoffer Valdemar Nissen, et al.
Diagnostics (Basel, Switzerland)|May 13, 2026
Edema as a Key Presentation of Acrodermatitis Chronica Atrophicans: A Retrospective Cohort Study from a Tertiary Setting in Denmark 2017-2025Otto Scharff El-Nasser, Helene Mens, Nanna Skaarup Andersen, et al.
American Journal of Clinical Dermatology|October 13, 2024
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort StudyMette Gyldenløve, Christoffer Valdemar Nissen, Sascha Dinsen Wreschner Stave, et al.
Dermatologic Therapy|September 1, 2020
Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasisValdemar Wendelboe Nielsen, Tamara Theresia Lund, Robert Gniadecki, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 2